Bessemer Group
RPRX icon

Bessemer Group’s Royalty Pharma RPRX Stock Holding History

Bessemer Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60K Sell
1,072
-22
-2% -$1.15K ﹤0.01% 1646
2026
Q1 		$53K Buy
1,094
+282
+35% +$12.4K ﹤0.01% 1660
2025
Q4 		$32K Buy
812
+461
+131% +$17.6K ﹤0.01% 1757
2025
Q3 		$13K Buy
+351
New +$12.7K ﹤0.01% 1863
2024
Q4 		– Sell
-241
Closed -$7K – 2655
2024
Q3 		$7K Buy
+241
New +$6.67K ﹤0.01% 1807
2023
Q4 		– Sell
-491
Closed -$13K – 2263
2023
Q3 		$13K Buy
+491
New +$14.6K ﹤0.01% 1536
2022
Q2 		– Sell
-170
Closed -$7K – 2007
2022
Q1 		$7K Hold
170
– – ﹤0.01% 1454
2021
Q4 		$7K Sell
170
-869
-84% -$33.8K ﹤0.01% 1506
2021
Q3 		$38K Buy
1,039
+869
+511% +$33.8K ﹤0.01% 1111
2021
Q2 		$7K Hold
170
– – ﹤0.01% 1396
2021
Q1 		$7K Buy
+170
New +$8.06K ﹤0.01% 1363

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bessemer Group's RPRX Position: Q2 2026 in Review

Bessemer Group reduced its Royalty Pharma (RPRX) stake by 2% in Q2 2026, selling an estimated $1.15K and leaving 1,072 shares worth $60K. The position accounts for ﹤0.01% of the portfolio, ranked #1646.

Bessemer Group first reported a position in RPRX in Q1 2021 and has held it in 11 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Bessemer Group held 1,072 shares of Royalty Pharma worth $60K as of Q2 2026.
  • Bessemer Group sold 22 Royalty Pharma shares in Q2 2026, an estimated $1.15K.
  • Royalty Pharma made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1646 holding.
  • Bessemer Group first reported a position in Royalty Pharma in Q1 2021 and has held it in 11 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.